Dr. Perl discusses results from the phase I CHRYSALIS trial, which investigated gilteritinitib in patients with relapsed/refractory acute myeloid leukemia.
Alexander Perl, MD: The New FLT3 Inhibitor Gilteritinib is “Well-Tolerated” in AML
Recent Articles
January 2019 Annual Meeting Edition
This issue features highlights from the 2018 ASH Annual Meeting, including big data initiatives to improve prognosis in myelodysplastic syndromes, and more.
ECHELON-2: Brentuximab Vedotin Combination Outperforms CHOP for Peripheral T-Cell Lymphomas
Results from the phase III ECHELON-2 trial showed that brentuximab vedotin added to a combination of cyclophosphamide, doxorubicin, and prednisone (BV+CHP) nearly doubled progression-free...
Selinexor Induces Deep Responses in Refractory Multiple Myeloma
More than one-quarter of patients with refractory multiple myeloma (MM) responded to treatment with a combination of selinexor and low-dose dexamethasone, according to results...
REACHing Children With Sickle Cell Anemia in Sub-Saharan Africa
Daily treatment with hydroxyurea was feasible, well-tolerated, and safe for children with sickle cell anemia (SCA) living in sub-Saharan Africa, according to results from...
Four Cycles as Effective as Six Cycles of Chemotherapy for Favorable-Risk DLBCL
While young patients with diffuse large B-cell lymphoma (DLBCL) are typically treated with six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), results from...
Current Issue
January 2019 Annual Meeting Edition
This issue features highlights from the 2018 ASH Annual Meeting, including big data initiatives to improve prognosis in myelodysplastic syndromes, and more.
